NCT00095017 2022-02-16
Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)
Organon and Co
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT00140894 2019-09-20
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 4 Terminated
NCT00092183 2017-05-05
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00092196 2017-05-05
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00097929 2017-04-07
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00091559 2017-04-05
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00092482 2017-03-22
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00517309 2017-03-22
FUTURE
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00418366 2015-08-19
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
Merck Sharp & Dohme LLC
Phase 1 Completed